iRhythm Technologies, Inc.
NASDAQ:IRTCMedical - Devices
+$0.36 today
- Market cap
- $3.19B
- Beta
- 1.28
- P/E (TTM)
- -119.5
- EPS (TTM)
- -$0.85
Volume 1.20M
Average 0.52M
IRTC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
iRhythm Technologies, Inc.NASDAQ: IRTC
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA turns negative
Q3 FY2026 EBITDA was -$32.56M, compared with $4.71M a year earlier. Trailing-twelve-month EBITDA was -$10.41M.
Context
- EBITDA amounted to 0.5% of revenue in FY2025, down 12.0 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of $42.88M (+1181.4%) for the fiscal year ending Dec 2026, a step up from the +94.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$32.56M-436.8% QoQ
- Last fiscal yearDec 2025
- -$3.97M+94.7% YoY
- LTMSep 2026
- -$10.41M+7.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -790.6% | -0.9% | +789.7 pp |
| 1 year | +94.7% | +1181.4% | +1086.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (3.97M) USD
- Year-over-year change
- +94.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.97M) | +94.7% |
| FY2024 | 2024-12-31 | (74.13M) | +23.5% |
| FY2023 | 2023-12-31 | (96.86M) | -5.1% |
| FY2022 | 2022-12-31 | (92.14M) | -10.7% |
| FY2021 | 2021-12-31 | (83.23M) | — |
EBITDA vs competitors
How IRTC compares with its peers on the latest reported figures
- IRTC's LTM Sep 2026 EBITDA of -$10.41M is the 6th highest of the 7 companies compared; the peer median is $216.82M.
- Its year-over-year change of +7.8% is the 6th highest of 7, against a peer median of +19.0%.
- EBITDA amounts to 1.2% of revenue for IRTC, versus a peer median of 21.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B | +9.8% | +4.1% | 27.3% | |
| LTM Jun 2026 | $5.8B | +23.2% | +23.0% | 27.6% | |
| LTM Jun 2026 | $222.27M | +14.8% | +95.5% | 14.8% | |
| LTM Sep 2026 | $211.36M | +363.4% | — | 14.0% | |
| LTM Jun 2026 | $37.73M | +508.5% | — | 6.6% | |
| LTM Sep 2026 | -$10.41M | +7.8% | — | 1.2% | |
| LTM Jan 2026 | -$128M | -87.3% | — | 152.9% | |
| Peer median (excluding IRTC) | $216.82M | +19.0% | +23.0% | 21.1% | |
Competitors are the stored peer set for IRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 322.83M | 410.92M | 492.68M | 591.84M | 747.14M |
| Cost of Revenue | 109.26M | 129.29M | 160.88M | 184.31M | 219.89M |
| Gross Profit | 213.57M | 281.63M | 331.81M | 407.53M | 527.25M |
| Gross Margin | 66.2% | 68.5% | 67.3% | 68.9% | 70.6% |
| Research & Development | 38.67M | 46.61M | 60.24M | 103.83M | 84.61M |
| Selling, General & Admin | 274.84M | 322.2M | 385.65M | 418.57M | 479.45M |
| Operating Expenses | 313.51M | 395.42M | 456.97M | 523.04M | 564.06M |
| Depreciation & Amortization | 16.59M | 19.61M | 22.14M | 25.78M | 26.48M |
| EBITDA | (83.23M) | (92.14M) | (96.86M) | (74.13M) | (3.97M) |
| EBITDA Margin | -25.8% | -22.4% | -19.7% | -12.5% | -0.5% |
| Operating Income | (99.94M) | (113.78M) | (125.16M) | (115.51M) | (36.81M) |
| Operating Margin | -31.0% | -27.7% | -25.4% | -19.5% | -4.9% |
| Interest Income | 118K | 2.35M | 6.16M | 21.94M | 21.52M |
| Interest Expense | 1.17M | 4.14M | 3.65M | 12.82M | 13.15M |
| Other Income / Expenses | (1.05M) | (2.1M) | 2.51M | 2.78M | (6.79M) |
| Income Before Tax | (100.99M) | (115.89M) | (122.66M) | (112.72M) | (43.6M) |
| Pre-Tax Margin | -31.3% | -28.2% | -24.9% | -19.0% | -5.8% |
| Income Tax Expense | 367K | 269K | 750K | 565K | 953K |
| Net Income | (101.36M) | (116.16M) | (123.41M) | (113.29M) | (44.55M) |
| Net Margin | -31.4% | -28.3% | -25.0% | -19.1% | -6.0% |
| EPS (Basic) | (3.46) | (3.88) | (4.04) | (3.63) | (1.39) |
| EPS (Diluted) | (3.46) | (3.88) | (4.04) | (3.63) | (1.39) |
| Weighted Avg Shares | 29.33M | 29.92M | 30.53M | 31.2M | 32M |
| Weighted Avg Shares (Diluted) | 29.33M | 29.92M | 30.53M | 31.2M | 32M |
iRhythm Technologies, Inc.
NASDAQ:IRTC
Intrinsic Alpha fair value
Locked
Current Price
$94.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.